RenovoRx, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 10.23 million compared to USD 9.89 million a year ago. Basic loss per share from continuing operations was USD 0.99 compared to USD 1.09 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.27 USD | +0.79% | -9.29% | -44.54% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.54% | 30.18M | |
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B |
- Stock Market
- Equities
- RNXT Stock
- News RenovoRx, Inc.
- RenovoRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023